Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations

Talazoparib (Talzenna, Pfizer) is indicated 'as monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or a taxane in the neo/adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine-based therapy, or be considered unsuitable for endocrine-based therapy'.

The dosage schedule is available in the summary of product characteristics for talazoparib.

£4,965 for a 30 pack of 1 mg capsules and £1,655 for a 30 pack of 0.25 mg capsules (excluding VAT; BNF online accessed July 2023).

The company has a commercial arrangement. This makes talazoparib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.